Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Income from Continuing Operations (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Income from Continuing Operations data on record, last reported at 17841919.0 in Q1 2026.

  • On a quarterly basis, Income from Continuing Operations fell 22.22% to 17841919.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 55218196.0, a 43.78% decrease, with the full-year FY2025 number at 51974283.0, down 81.8% from a year prior.
  • Income from Continuing Operations reached 17841919.0 in Q1 2026 per IKT's latest filing, down from 13775626.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for IKT hit a ceiling of 4334974.0 in Q4 2022 and a floor of 17841919.0 in Q1 2026.
  • A 5-year average of 8035596.59 and a median of 5050535.0 in 2024 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: rose 18.57% in 2024, then plummeted 205.25% in 2025.
  • Tracing IKT's Income from Continuing Operations over 5 years: stood at 4334974.0 in 2022, then dropped by 1.58% to 4403566.0 in 2023, then plummeted by 193.6% to 12928700.0 in 2024, then fell by 6.55% to 13775626.0 in 2025, then decreased by 29.52% to 17841919.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for IKT at 17841919.0 in Q1 2026, 13775626.0 in Q4 2025, and 12768373.0 in Q3 2025.